Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
IMBRUVICA®
(ibrutinib) Capsules and Tablets for Oral Use
Ibrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK). It is a white to off-white solid with the empirical formula C25H24N6O2 and a molecular weight 440.50. Ibrutinib is freely soluble in dimethyl sulfoxide, soluble in methanol and practically insoluble in water.
The chemical name for ibrutinib is 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1Hpyrazolo[ 3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one and has the following structure:
 |
IMBRUVICA (ibrutinib) is available as immediate-release oral capsules and immediate-release oral tablets.
IMBRUVICA (ibrutinib) capsules for oral administration are available in the following dosage strengths: 70 mg and 140 mg. Each capsule contains ibrutinib (active ingredient) and the following inactive ingredients: croscarmellose sodium, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate. The capsule shell contains gelatin, titanium dioxide, yellow iron oxide (70 mg capsule only), and black ink.
IMBRUVICA (ibrutinib) tablets for oral administration are available in the following dosage strengths: 140 mg, 280 mg, 420 mg, and 560 mg. Each tablet contains ibrutinib (active ingredient) and the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, and sodium lauryl sulfate. The film coating for each tablet contains ferrosoferric oxide (140 mg, 280 mg, and 420 mg tablets), polyvinyl alcohol, polyethylene glycol, red iron oxide (280 mg and 560 mg tablets), talc, titanium dioxide, and yellow iron oxide (140 mg, 420 mg, and 560 mg tablets).
IMBRUVICA is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Accelerated approval was granted for this indication based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial [see Clinical Studies].
IMBRUVICA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
IMBRUVICA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with 17p deletion.
IMBRUVICA is indicated for the treatment of adult patients with Waldenström's macroglobulinemia (WM).
IMBRUVICA is indicated for the treatment of adult patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.
Accelerated approval was granted for this indication based on overall response rate [see Clinical Studies]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
IMBRUVICA is indicated for the treatment of adult patients with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy.
Administer IMBRUVICA orally once daily at approximately the same time each day. The dose should be taken orally with a glass of water. Do not open, break, or chew the capsules. Do not cut, crush, or chew the tablets.
The recommended dose of IMBRUVICA for MCL and MZL is 560 mg orally once daily until disease progression or unacceptable toxicity.
The recommended dose of IMBRUVICA for CLL/SLL and WM as a single agent, in combination with rituximab for WM, or in combination with bendamustine and rituximab for CLL/SLL is 420 mg orally once daily until disease progression or unacceptable toxicity.
When administering IMBRUVICA in combination with rituximab, consider administering IMBRUVICA prior to rituximab when given on the same day.
The recommended dose of IMBRUVICA for cGVHD is 420 mg orally once daily until cGVHD progression, recurrence of an underlying malignancy, or unacceptable toxicity. When a patient no longer requires therapy for the treatment of cGVHD, IMBRUVICA should be discontinued considering the medical assessment of the individual patient.
Interrupt IMBRUVICA therapy for any Grade 3 or greater non-hematological toxicities, Grade 3 or greater neutropenia with infection or fever, or Grade 4 hematological toxicities. Once the symptoms of the toxicity have resolved to Grade 1 or baseline (recovery), IMBRUVICA therapy may be reinitiated at the starting dose. If the toxicity reoccurs, reduce dose by 140 mg per day. A second reduction of dose by 140 mg may be considered as needed. If these toxicities persist or recur following two dose reductions, discontinue IMBRUVICA.
Recommended dose modifications are described below:
| Toxicity Occurrence | Dose Modification for MCL and MZL After Recovery Starting Dose = 560 mg | Dose Modification for CLL/SLL, WM, and cGVHD After Recovery Starting Dose = 420 mg |
| First | Restart at 560 mg daily | Restart at 420 mg daily |
| Second | Restart at 420 mg daily | Restart at 280 mg daily |
| Third | Restart at 280 mg daily | Restart at 140 mg daily |
| Fourth | Discontinue IMBRUVICA | Discontinue IMBRUVICA |
Recommended dose modifications are described below [see DRUG INTERACTIONS]:
| Patient Population | Coadministered Drug | Recommended IMBRUVICA Dose |
| B-Cell Malignancies |
|
280 mg once daily Modify dose as recommended [see Dose Modifications for Adverse Reactions]. |
|
140 mg once daily Modify dose as recommended [see Dose Modifications for Adverse Reactions]. | |
|
70 mg once daily Interrupt dose as recommended [see Dose Modifications for Adverse Reactions]. | |
|
Avoid concomitant use. If these inhibitors will be used shortterm (such as anti-infectives for seven days or less), interrupt IMBRUVICA. | |
| Chronic Graft versus Host Disease |
|
420 mg once daily Modify dose as recommended [see Dose Modifications for Adverse Reactions]. |
|
280 mg once daily Modify dose as recommended [see Dose Modifications for Adverse Reactions]. | |
|
140 mg once daily Interrupt dose as recommended [see Dose Modifications for Adverse Reactions]. | |
|
Avoid concomitant use. If these inhibitors will be used shortterm (such as anti-infectives for seven days or less), interrupt IMBRUVICA. |
After discontinuation of a CYP3A inhibitor, resume previous dose of IMBRUVICA [see Recommended Dosage and DRUG INTERACTIONS].
The recommended dose is 140 mg daily for patients with mild hepatic impairment (Child-Pugh class A).
The recommended dose is 70 mg daily for patients with moderate hepatic impairment (Child- Pugh class B).
Avoid the use of IMBRUVICA in patients with severe hepatic impairment (Child-Pugh class C) [see Use In Specific Populations and CLINICAL PHARMACOLOGY].
If a dose of IMBRUVICA is not taken at the scheduled time, it can be taken as soon as possible on the same day with a return to the normal schedule the following day. Extra doses of IMBRUVICA should not be taken to make up for the missed dose.
Each 70 mg capsule is a yellow, opaque capsule marked with “ibr 70 mg” in black ink.
Each 140 mg capsule is a white, opaque capsule marked with “ibr 140 mg” in black ink.
Each 140 mg tablet is a yellow green to green round tablet debossed with “ibr” on one side and “140” on the other side.
Each 280 mg tablet is a purple oblong tablet debossed with “ibr” on one side and “280” on the other side.
Each 420 mg tablet is a yellow green to green oblong tablet debossed with “ibr” on one side and “420” on the other side.
Each 560 mg tablet is a yellow to orange oblong tablet debossed with “ibr” on one side and “560” on the other side.
The 70 mg capsules are supplied as yellow opaque capsules, marked with “ibr 70 mg” in black ink, and are available in white HDPE bottles with a child-resistant closure:
28 capsules per bottle: NDC 57962-070-28
The 140 mg capsules are supplied as white opaque capsules, marked with “ibr 140 mg” in black ink, and are available in white HDPE bottles with a child-resistant closure:
90 capsules per bottle: NDC 57962-140-09
120 capsules per bottle: NDC 57962-140-12
Store bottles at room temperature 20°C to 25°C (68°F to 77°F). Excursions are permitted between 15°C and 30°C (59°F to 86°F). Retain in original package until dispensing.
The IMBRUVICA (ibrutinib) tablets are supplied in 4 strengths in the following packaging configurations:
140 mg tablets: Yellow green to green round tablets debossed with “ibr” on one side and “140” on the other side. Carton of one folded blister card containing two 14-count blister strips for a total of 28 tablets: NDC 57962-014-28
280 mg tablets: Purple oblong tablets debossed with “ibr” on one side and “280” on the other side. Carton of one folded blister card containing two 14-count blister strips for a total of 28 tablets: NDC 57962-280-28
420 mg tablets: Yellow green to green oblong tablets debossed with “ibr” on one side and “420” on the other side. Carton of one folded blister card containing two 14-count blister strips for a total of 28 tablets: NDC 57962-420-28
560 mg tablets: Yellow to orange oblong tablets debossed with “ibr” on one side and “560” on the other side. Carton of one folded blister card containing two 14-count blister strips for a total of 28 tablets: NDC 57962-560-28
Store tablets in original packaging at room temperature 20°C to 25°C (68°F to 77°F). Excursions are permitted between 15°C and 30°C (59°F to 86°F).
Distributed and Marketed by: Pharmacyclics LLC, Sunnyvale, CA USA 94085 and Marketed by: Janssen Biotech, Inc., Horsham, PA USA 19044. Revised: Aug 2018
The following adverse reactions are discussed in more detail in other sections of the labeling:
Because clinical trials are conducted under widely variable conditions, adverse event rates observed in clinical trials of a drug cannot be directly compared with rates of clinical trials of another drug and may not reflect the rates observed in practice.
The data described below reflect exposure to IMBRUVICA in a clinical trial (Study 1104) that included 111 patients with previously treated MCL treated with 560 mg daily with a median treatment duration of 8.3 months.
The most commonly occurring adverse reactions (≥ 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see Tables 1 and 2).
The most common Grade 3 or 4 non-hematological adverse reactions (≥ 5%) were pneumonia, abdominal pain, atrial fibrillation, diarrhea, fatigue, and skin infections.
Fatal and serious cases of renal failure have occurred with IMBRUVICA therapy. Increases in creatinine 1.5 to 3 times the upper limit of normal occurred in 9% of patients.
Adverse reactions from the MCL trial (N=111) using single agent IMBRUVICA 560 mg daily occurring at a rate of ≥ 10% are presented in Table 1.
Table 1: Non-Hematologic Adverse Reactions in
≥ 10% of Patients with MCL (N=111)
| Body System | Adverse Reaction | All Grades (%) | Grade 3 or 4 (%) |
| Gastrointestinal disorders | Diarrhea | 51 | 5 |
| Nausea | 31 | 0 | |
| Constipation | 25 | 0 | |
| Abdominal pain | 24 | 5 | |
| Vomiting | 23 | 0 | |
| Stomatitis | 17 | 1 | |
| Dyspepsia | 11 | 0 | |
| Infections and infestations | Upper respiratory tract infection | 34 | 0 |
| Urinary tract infection | 14 | 3 | |
| Pneumonia | 14 | 7 | |
| Skin infections | 14 | 5 | |
| Sinusitis | 13 | 1 | |
| General disorders and administration site conditions | Fatigue | 41 | 5 |
| Peripheral edema | 35 | 3 | |
| Pyrexia | 18 | 1 | |
| Asthenia | 14 | 3 | |
| Skin and subcutaneous tissue disorders | Bruising | 30 | 0 |
| Rash | 25 | 3 | |
| Petechiae | 11 | 0 | |
| Musculoskeletal and connective tissue disorders | Musculoskeletal pain | 37 | 1 |
| Muscle spasms | 14 | 0 | |
| Arthralgia | 11 | 0 | |
| Respiratory, thoracic and mediastinal disorders | Dyspnea | 27 | 4 |
| Cough | 19 | 0 | |
| Epistaxis | 11 | 0 | |
| Metabolism and nutrition disorders | Decreased appetite | 21 | 2 |
| Dehydration | 12 | 4 | |
| Nervous system disorders | Dizziness | 14 | 0 |
| Headache | 13 | 0 |
Table 2: Treatment-Emergent* Hematologic Laboratory
Abnormalities in Patients with MCL (N=111)
| Percent of Patients (N=111) |
||
| All Grades (%) | Grade 3 or 4 (%) | |
| Platelets Decreased | 57 | 17 |
| Neutrophils Decreased | 47 | 29 |
| Hemoglobin Decreased | 41 | 9 |
| * Based on laboratory measurements and adverse reactions | ||
Ten patients (9%) discontinued treatment due to adverse reactions in the trial (N=111). The most frequent adverse reaction leading to treatment discontinuation was subdural hematoma (1.8%). Adverse reactions leading to dose reduction occurred in 14% of patients.
Patients with MCL who develop lymphocytosis greater than 400,000/mcL have developed intracranial hemorrhage, lethargy, gait instability, and headache. However, some of these cases were in the setting of disease progression.
Forty percent of patients had elevated uric acid levels on study including 13% with values above 10 mg/dL. Adverse reaction of hyperuricemia was reported for 15% of patients.
The data described below reflect exposure in one single-arm, open-label clinical trial (Study 1102) and three randomized controlled clinical trials (RESONATE, RESONATE-2, and HELIOS) in patients with CLL/SLL (n=1278 total and n=668 patients exposed to IMBRUVICA). Study 1102 included 51 patients with previously treated CLL/SLL, RESONATE included 391 randomized patients with previously treated CLL or SLL who received single agent IMBRUVICA or ofatumumab, RESONATE-2 included 269 randomized patients 65 years or older with treatment naive-CLL or SLL who received single agent IMBRUVICA or chlorambucil, and HELIOS included 578 randomized patients with previously treated CLL or SLL who received IMBRUVICA in combination with bendamustine and rituximab or placebo in combination with bendamustine and rituximab.
The most commonly occurring adverse reactions in Studies 1102, RESONATE, RESONATE-2, and HELIOS in patients with CLL/SLL receiving IMBRUVICA (≥ 20%) were neutropenia, thrombocytopenia, anemia, diarrhea, musculoskeletal pain, nausea, rash, bruising, fatigue, pyrexia and hemorrhage. Four to 10 percent of patients receiving IMBRUVICA in Studies 1102, RESONATE, RESONATE-2, and HELIOS discontinued treatment due to adverse reactions. These included pneumonia, hemorrhage, atrial fibrillation, rash and neutropenia (1% each). Adverse reactions leading to dose reduction occurred in approximately 6% of patients.
Adverse reactions and laboratory abnormalities from the CLL/SLL trial (N=51) using single agent IMBRUVICA 420 mg daily in patients with previously treated CLL/SLL occurring at a rate of ≥ 10% with a median duration of treatment of 15.6 months are presented in Tables 3 and 4.
Table 3: Non-Hematologic Adverse Reactions in
≥ 10% of Patients with CLL/SLL (N=51) in Study 1102
| Body System | Adverse Reaction | All Grades (%) | Grade 3 or 4 (%) |
| Gastrointestinal disorders | Diarrhea | 59 | 4 |
| Constipation | 22 | 2 | |
| Nausea | 20 | 2 | |
| Stomatitis | 20 | 0 | |
| Vomiting | 18 | 2 | |
| Abdominal pain | 14 | 0 | |
| Dyspepsia | 12 | 0 | |
| Infections and infestations | Upper respiratory tract | ||
| infection | 47 | 2 | |
| Sinusitis | 22 | 6 | |
| Skin infection | 16 | 6 | |
| Pneumonia | 12 | 10 | |
| Urinary tract infection | 12 | 2 | |
| General disorders and administration site conditions | Fatigue | 33 | 6 |
| Pyrexia | 24 | 2 | |
| Peripheral edema | 22 | 0 | |
| Asthenia | 14 | 6 | |
| Chills | 12 | 0 | |
| Skin and subcutaneous tissue disorders | Bruising | 51 | 2 |
| Rash | 25 | 0 | |
| Petechiae | 16 | 0 | |
| Respiratory, thoracic and mediastinal disorders | Cough | 22 | 0 |
| Oropharyngeal pain | 14 | 0 | |
| Dyspnea | 12 | 0 | |
| Musculoskeletal and connective tissue disorders | Musculoskeletal pain | 25 | 6 |
| Arthralgia | 24 | 0 | |
| Muscle spasms | 18 | 2 | |
| Nervous system disorders | Dizziness | 20 | 0 |
| Headache | 18 | 2 | |
| Metabolism and nutrition disorders | Decreased appetite | 16 | 2 |
| Neoplasms benign, malignant, unspecified | Second malignancies* | 12* | 0 |
| Vascular disorders | Hypertension | 16 | 8 |
| *One patient death due to histiocytic sarcoma. | |||
Table 4: Treatment-Emergent* Hematologic Laboratory
Abnormalities in Patients with CLL/SLL (N=51) in Study 1102
| Percent of Patients (N=51) |
||
| All Grades (%) | Grade 3 or 4 (%) | |
| Platelets Decreased | 69 | 12 |
| Neutrophils Decreased | 53 | 26 |
| Hemoglobin Decreased | 43 | 0 |
| * Based on laboratory measurements per IWCLL criteria and adverse reactions. | ||
Adverse reactions and laboratory abnormalities described below in Tables 5 and 6 reflect exposure to IMBRUVICA with a median duration of 8.6 months and exposure to ofatumumab with a median of 5.3 months in RESONATE in patients with previously treated CLL/SLL.
Table 5: Adverse Reactions Reported in ≥
10% of Patients and at Least 2% Greater in the IMBRUVICA Treated Arm in
Patients with CLL/SLL in RESONATE
| Body System Adverse Reaction | IMBRUVICA (N=195) |
Ofatumumab (N=191) |
||
| All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%) | |
| Gastrointestinal disorders | ||||
| Diarrhea | 48 | 4 | 18 | 2 |
| Nausea | 26 | 2 | 18 | 0 |
| Stomatitis* | 17 | 1 | 6 | 1 |
| Constipation | 15 | 0 | 9 | 0 |
| Vomiting | 14 | 0 | 6 | 1 |
| General disorders and administration site conditions | ||||
| Pyrexia | 24 | 2 | 15 | 1 |
| Infections and infestations | ||||
| Upper respiratory tract infection | 16 | 1 | 11 | 2 |
| Pneumonia* | 15 | 10 | 13 | 9 |
| Sinusitis* | 11 | 1 | 6 | 0 |
| Urinary tract infection | 10 | 4 | 5 | 1 |
| Skin and subcutaneous tissue disorders | ||||
| Rash* | 24 | 3 | 13 | 0 |
| Petechiae | 14 | 0 | 1 | 0 |
| Bruising* | 12 | 0 | 1 | 0 |
| Musculoskeletal and connective tissue disorders | ||||
| Musculoskeletal pain* | 28 | 2 | 18 | 1 |
| Arthralgia | 17 | 1 | 7 | 0 |
| Nervous system disorders | ||||
| Headache | 14 | 1 | 6 | 0 |
| Dizziness | 11 | 0 | 5 | 0 |
| Injury, poisoning and procedural complications | ||||
| Contusion | 11 | 0 | 3 | 0 |
| Eye disorders | ||||
| Vision blurred | 10 | 0 | 3 | 0 |
| Subjects with multiple events for a given ADR term are
counted once only for each ADR term. The body system and individual ADR terms are sorted in descending frequency order in the IMBRUVICA arm. * Includes multiple ADR terms |
||||
Table 6: Treatment-Emergent Hematologic Laboratory
Abnormalities in Patients with CLL/SLL in RESONATE
| IMBRUVICA (N=195) |
Ofatumumab (N=191) |
|||
| All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%) | |
| Neutrophils Decreased | 51 | 23 | 57 | 26 |
| Platelets Decreased | 52 | 5 | 45 | 10 |
| Hemoglobin Decreased | 36 | 0 | 21 | 0 |
Adverse reactions described below in Table 7 reflect exposure to IMBRUVICA with a median duration of 17.4 months. The median exposure to chlorambucil was 7.1 months in RESONATE-2.
Table 7: Adverse Reactions Reported in ≥
10% of Patients and at Least 2% Greater in the IMBRUVICA Treated Arm in
Patients with CLL/SLL in RESONATE-2
| Body System Adverse Reaction | IMBRUVICA (N=135) |
Chlorambucil (N=132) |
||
| All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%) | |
| Gastrointestinal disorders | ||||
| Diarrhea | 42 | 4 | 17 | 0 |
| Stomatitis* | 14 | 1 | 4 | 1 |
| Musculoskeletal and connective tissue disorders | ||||
| Musculoskeletal pain* | 36 | 4 | 20 | 0 |
| Arthralgia | 16 | 1 | 7 | 1 |
| Muscle spasms | 11 | 0 | 5 | 0 |
| Eye disorders | ||||
| Dry eye | 17 | 0 | 5 | 0 |
| Lacrimation increased | 13 | 0 | 6 | 0 |
| Vision blurred | 13 | 0 | 8 | 0 |
| Visual acuity reduced | 11 | 0 | 2 | 0 |
| Skin and subcutaneous tissue disorders | ||||
| Rash* | 21 | 4 | 12 | 2 |
| Bruising* | 19 | 0 | 7 | 0 |
| Infections and infestations | ||||
| Skin infection* | 15 | 2 | 3 | 1 |
| Pneumonia* | 14 | 8 | 7 | 4 |
| Urinary tract infections | 10 | 1 | 8 | 1 |
| Respiratory, thoracic and mediastinal disorders | ||||
| Cough | 22 | 0 | 15 | 0 |
| General disorders and administration site conditions | ||||
| Peripheral edema | 19 | 1 | 9 | 0 |
| Pyrexia | 17 | 0 | 14 | 2 |
| Vascular disorders | ||||
| Hypertension* | 14 | 4 | 1 | 0 |
| Nervous system disorders | ||||
| Headache | 12 | 1 | 10 | 2 |
| Subjects with multiple events for a given ADR term are
counted once only for each ADR term. The body system and individual ADR terms are sorted in descending frequency order in the IMBRUVICA arm. * Includes multiple ADR terms |
||||
Adverse reactions described below in Table 8 reflect exposure to IMBRUVICA + BR with a median duration of 14.7 months and exposure to placebo + BR with a median of 12.8 months in HELIOS in patients with previously treated CLL/SLL.
Table 8: Adverse Reactions Reported in at Least 10% of
Patients and at Least 2% Greater in the IMBRUVICA Arm in Patients with CLL/SLL
in HELIOS
| Body System Adverse Reaction | Ibrutinib + BR (N=287) |
Placebo + BR (N=287) |
||
| All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%) | |
| Blood and lymphatic system disorders | ||||
| Neutropenia* | 66 | 61 | 60 | 55 |
| Thrombocytopenia* | 34 | 16 | 26 | 16 |
| Skin and subcutaneous tissue disorders | ||||
| Rash * | 32 | 4 | 25 | 1 |
| Bruising * | 20 | <1 | 8 | <1 |
| Gastrointestinal disorders | ||||
| Diarrhea | 36 | 2 | 23 | 1 |
| Abdominal pain | 12 | 1 | 8 | <1 |
| Musculoskeletal and connective tissue disorders | ||||
| Musculoskeletal pain* | 29 | 2 | 20 | 0 |
| Muscle spasms | 12 | <1 | 5 | 0 |
| General disorders and administration site conditions | ||||
| Pyrexia | 25 | 4 | 22 | 2 |
| Vascular disorders | ||||
| Hemorrhage* | 19 | 2 | 9 | 1 |
| Hypertension * | 11 | 5 | 5 | 2 |
| Infections and infestations | ||||
| Bronchitis | 13 | 2 | 10 | 3 |
| Skin infection* | 10 | 3 | 6 | 2 |
| Metabolism and nutrition disorders | ||||
| Hyperuricemia | 10 | 2 | 6 | 0 |
| The body system and individual ADR terms are sorted in
descending frequency order in the IMBRUVICA arm. * Includes multiple ADR terms <1 used for frequency above 0 and below 0.5% |
||||
Atrial fibrillation of any grade occurred in 7% of patients treated with IMBRUVICA + BR and 2% of patients treated with placebo + BR. The frequency of Grade 3 and 4 atrial fibrillation was 3% in patients treated with IMBRUVICA + BR and 1% in patients treated with placebo + BR.
The data described below reflect exposure to IMBRUVICA in three single-arm open-label clinical trials (Study 1118, Study 1121, and INNOVATE monotherapy arm) and one randomized controlled trial (INNOVATE) in patients with WM or MZL, including a total n=307 patients overall and n=232 patients exposed to IMBRUVICA. Study 1118 included 63 patients with previously treated WM who received single agent IMBRUVICA. Study 1121 included 63 patients with previously treated MZL who received single agent IMBRUVICA. INNOVATE included 150 patients with treatment naive or previously treated WM who received IMBRUVICA or placebo in combination with rituximab. The INNOVATE monotherapy arm included 31 patients with previously treated WM who failed prior rituximab-containing therapy and received IMBRUVICA.
The most commonly occurring adverse reactions in Studies 1118, 1121, and INNOVATE (≥ 20%) were thrombocytopenia, diarrhea, bruising, neutropenia, musculoskeletal pain, hemorrhage, anemia, rash, fatigue, and nausea.
Seven percent of patients receiving IMBRUVICA across Studies 1118, 1121, and INNOVATE discontinued treatment due to adverse reactions. The most common adverse reactions leading to discontinuation were atrial fibrillation, interstitial lung disease, diarrhea and rash. Adverse reactions leading to dose reduction occurred in 13% of patients.
Adverse reactions and laboratory abnormalities described below in Tables 9 and 10 reflect exposure to IMBRUVICA with a median duration of 11.7 months in Study 1118 and 33 months in the INNOVATE Monotherapy Arm.
Table 9: Non-Hematologic Adverse Reactions in
≥ 10% in Patients with WM in Study 1118 and the INNOVATE Monotherapy Arm
(N=94)
| Body System | Adverse Reaction | All Grades (%) | Grade 3 or 4 (%) |
| Gastrointestinal disorders | Diarrhea | 38 | 2 |
| Nausea | 21 | 0 | |
| Stomatitis* | 15 | 0 | |
| Constipation | 12 | 1 | |
| Gastroesophageal reflux disease | 12 | 0 | |
| Skin and subcutaneous tissue disorders | Bruising* | 28 | 1 |
| Rash* | 21 | 1 | |
| Vascular disorders | Hemorrhage* | 28 | 0 |
| Hypertension* | 14 | 4 | |
| General disorders and administrative site conditions | Fatigue | 18 | 2 |
| Pyrexia | 12 | 2 | |
| Musculoskeletal and connective tissue disorders | Musculoskeletal pain* | 21 | 0 |
| Muscle spasms | 19 | 0 | |
| Infections and infestations | Upper respiratory tract infection | 19 | 0 |
| Skin infection* | 18 | 3 | |
| Sinusitis* | 16 | 0 | |
| Pneumonia* | 13 | 5 | |
| Nervous system disorders | Headache | 14 | 0 |
| Dizziness | 13 | 0 | |
| Respiratory, thoracic and mediastinal disorders | Cough | 13 | 0 |
| The body system and individual ADR preferred terms are
sorted in descending frequency order. * Includes multiple ADR terms. |
|||
Table 10: Treatment-Emergent Hematologic Laboratory
Abnormalities in Patients with WM in Study 1118 and the INNOVATE Monotherapy
Arm (N=94)
| Percent of Patients (N=94) |
||
| All Grades (%) | Grade 3 or 4 (%) | |
| Platelets Decreased | 38 | 11 |
| Neutrophils Decreased | 43 | 16 |
| Hemoglobin Decreased | 21 | 6 |
Adverse reactions described below in Table 11 reflect exposure to IMBRUVICA + R with a median duration of 25.8 months and exposure to placebo + R with a median duration of 15.5 months in patients with treatment naive or previously treated WM in INNOVATE.
Table 11: Adverse Reactions Reported in at Least 10%
of Patients and at Least 2% Greater in the IMBRUVICA Arm in Patients with WM in
INNOVATE
| Body System Adverse Reaction | IMBRUVICA + R (N=75) |
Placebo + R (N=75) |
||
| All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%) | |
| Skin and subcutaneous tissue disorders | ||||
| Bruising* | 37 | 1 | 5 | 0 |
| Rash* | 24 | 1 | 11 | 0 |
| Musculoskeletal and connective tissue disorders | ||||
| Musculoskeletal pain* | 35 | 4 | 21 | 3 |
| Arthralgia | 24 | 3 | 11 | 1 |
| Muscle spasms | 17 | 0 | 12 | 1 |
| Vascular disorders | ||||
| Hemorrhage* | 32 | 3 | 17 | 3 |
| Hypertension* | 20 | 13 | 5 | 4 |
| Gastrointestinal disorders | ||||
| Diarrhea | 28 | 0 | 15 | 1 |
| Nausea | 21 | 0 | 12 | 0 |
| Dyspepsia | 16 | 0 | 1 | 0 |
| Constipation | 13 | 1 | 11 | 1 |
| Infections and infestations | ||||
| Pneumonia* | 19 | 13 | 5 | 3 |
| Skin infection* | 17 | 3 | 3 | 0 |
| Urinary tract infection | 13 | 0 | 0 | 0 |
| Bronchitis | 12 | 3 | 7 | 0 |
| Influenza | 12 | 0 | 7 | 1 |
| Viral upper respiratory tract infection | 11 | 0 | 7 | 0 |
| General disorders and administration site conditions | ||||
| Peripheral edema | 17 | 0 | 12 | 1 |
| Respiratory, thoracic, and mediastinal disorders | ||||
| Cough | 17 | 0 | 11 | 0 |
| Blood and Lymphatic System Disorders | ||||
| Neutropenia* | 16 | 12 | 11 | 4 |
| Cardiac Disorders | ||||
| Atrial fibrillation | 15 | 12 | 3 | 1 |
| Nervous system disorders | ||||
| Dizziness | 11 | 0 | 7 | 0 |
| Psychiatric disorders | ||||
| Insomnia | 11 | 0 | 4 | 0 |
| Metabolism and nutrition disorders | ||||
| Hypokalemia | 11 | 0 | 1 | 1 |
| The body system and individual ADR preferred terms are
sorted in descending frequency order. * Includes multiple ADR terms. |
||||
Grade 3 or 4 infusion related reactions were observed in 1% of patients treated with IMBRUVICA + R.
Adverse reactions and laboratory abnormalities described below in Tables 12 and 13 reflect exposure to IMBRUVICA with a median duration of 11.6 months in Study 1121.
Table 12: Non-Hematologic Adverse Reactions in ≥
10% in Patients with MZL in Study 1121 (N=63)
| Body System | Adverse Reaction | All Grades (%) | Grade 3 or 4 (%) |
| Gastrointestinal disorders | Diarrhea | 43 | 5 |
| Nausea | 25 | 0 | |
| Dyspepsia | 19 | 0 | |
| Stomatitis* | 17 | 2 | |
| Abdominal pain | 16 | 2 | |
| Constipation | 14 | 0 | |
| Abdominal pain upper | 13 | 0 | |
| Vomiting | 11 | 2 | |
| General disorders and administrative site conditions | Fatigue | 44 | 6 |
| Peripheral edema | 24 | 2 | |
| Pyrexia | 17 | 2 | |
| Skin and subcutaneous tissue disorders | Bruising * | 41 | 0 |
| Rash* | 29 | 5 | |
| Pruritus | 14 | 0 | |
| Musculoskeletal and connective tissue disorders | Musculoskeletal pain* | 40 | 3 |
| Arthralgia | 24 | 2 | |
| Muscle spasms | 19 | 3 | |
| Infections and infestations | Upper respiratory tract infection | 21 | 0 |
| Sinusitis* | 19 | 0 | |
| Bronchitis | 11 | 0 | |
| Pneumonia* | 11 | 10 | |
| Metabolism and nutrition disorders | Decreased appetite | 16 | 2 |
| Hyperuricemia | 16 | 0 | |
| Hypoalbuminemia | 14 | 0 | |
| Hypokalemia | 13 | 0 | |
| Vascular disorders | Hemorrhage* | 30 | 0 |
| Hypertension* | 14 | 5 | |
| Respiratory, thoracic and mediastinal disorders | Cough | 22 | 2 |
| Dyspnea | 21 | 2 | |
| Nervous system disorders | Dizziness | 19 | 0 |
| Headache | 13 | 0 | |
| Psychiatric disorders | Anxiety | 16 | 2 |
| The body system and individual ADR preferred terms are
sorted in descending frequency order. * Includes multiple ADR terms. |
|||
Table 13: Treatment-Emergent Hematologic Laboratory
Abnormalities in Patients with MZL in Study 1121 (N=63)
| Percent of Patients (N=63) |
||
| All Grades (%) | Grade 3 or 4 (%) | |
| Platelets Decreased | 49 | 6 |
| Hemoglobin Decreased | 43 | 13 |
| Neutrophils Decreased | 22 | 13 |
The data described below reflect exposure to IMBRUVICA in an open-label clinical trial (Study 1129) that included 42 patients with cGVHD after failure of first line corticosteroid therapy and required additional therapy.
The most commonly occurring adverse reactions in the cGVHD trial (≥ 20%) were fatigue, bruising, diarrhea, thrombocytopenia, stomatitis, muscle spasms, nausea, hemorrhage, anemia, and pneumonia. Atrial fibrillation occurred in one patient (2%) which was Grade 3.
Twenty-four percent of patients receiving IMBRUVICA in the cGVHD trial discontinued treatment due to adverse reactions. The most common adverse reactions leading to discontinuation were fatigue and pneumonia. Adverse reactions leading to dose reduction occurred in 26% of patients.
Adverse reactions and laboratory abnormalities described below in Tables 14 and 15 reflect exposure to IMBRUVICA with a median duration of 4.4 months in the cGVHD trial.
Table 14: Non-Hematologic Adverse Reactions in ≥
10% of Patients with cGVHD (N=42)
| Body System | Adverse Reaction | All Grades (%) | Grade 3 or 4 (%) |
| General disorders and administration site conditions | Fatigue | 57 | 12 |
| Pyrexia | 17 | 5 | |
| Edema peripheral | 12 | 0 | |
| Skin and subcutaneous tissue disorders | Bruising* | 40 | 0 |
| Rash* | 12 | 0 | |
| Gastrointestinal disorders | Diarrhea | 36 | 10 |
| Stomatitis* | 29 | 2 | |
| Nausea | 26 | 0 | |
| Constipation | 12 | 0 | |
| Musculoskeletal and connective tissue disorders | Muscle spasms | 29 | 2 |
| Musculoskeletal pain* | 14 | 5 | |
| Vascular disorders | Hemorrhage* | 26 | 0 |
| Infections and infestations | Pneumonia* | 21 | 10 |
| Upper respiratory tract infection | 19 | 0 | |
| Sepsis* | 10 | 10 | |
| Nervous system disorders | Headache | 17 | 5 |
| Injury, poisoning and procedural complications | Fall | 17 | 0 |
| Respiratory, thoracic and | Cough | 14 | 0 |
| mediastinal disorders | Dyspnea | 12 | 2 |
| Metabolism and nutrition disorders | Hypokalemia | 12 | 7 |
| The system organ class and individual ADR preferred terms
are sorted in descending frequency order. * Includes multiple ADR terms. |
|||
Table 15: Treatment-Emergent Hematologic Laboratory
Abnormalities in Patients with cGVHD (N=42)
| Percent of Patients (N=42) |
||
| All Grades (%) | Grade 3 or 4 (%) | |
| Platelets Decreased | 33 | 0 |
| Neutrophils Decreased | 10 | 10 |
| Hemoglobin Decreased | 24 | 2 |
In randomized controlled trials (n=1377; median treatment duration of 14.0 months for patients treated with IMBRUVICA and 7.5 months for patients in the control arm), the incidence of ventricular tachyarrhythmias (ventricular extrasystoles, ventricular arrhythmias, ventricular fibrillation, ventricular flutter, and ventricular tachycardia) of any grade was 1.0% versus 0.4% and of Grade 3 or greater was 0.2% versus 0% in patients treated with IMBRUVICA compared to patients in the control arm. In addition, the incidence of atrial fibrillation and atrial flutter of any grade was 8% versus 2% and for Grade 3 or greater was 4% versus 0.4% in patients treated with IMBRUVICA compared to patients in the control arm.
Diarrhea of any grade occurred at a rate of 40% of patients treated with IMBRUVICA compared to 19% of patients in the control arm. Grade 3 diarrhea occurred in 3% versus 1% of IMBRUVICA-treated patients compared to the control arm, respectively. The median time to first onset was 21 days (range: 0 to 475) versus 47 days (range: 0 to 492) for any grade diarrhea and 77 days (range: 3 to 310) versus 194 days (range: 11 to 325) for Grade 3 diarrhea in IMBRUVICA-treated patients compared to the control arm, respectively. Of the patients who reported diarrhea, 84% versus 88% had complete resolution, and 16% versus 12% had not reported resolution at time of analysis in IMBRUVICA-treated patients compared to the control arm, respectively. The median time from onset to resolution in IMBRUVICA-treated subjects was 6 days (range: 1 to 655) versus 5 days (range: 1 to 367) for any grade diarrhea and 6 days (range: 1 to 78) versus 19 days (range: 1 to 56) for Grade 3 diarrhea in IMBRUVICA-treated subjects compared to the control arm, respectively. Less than 1% of subjects discontinued IMBRUVICA due to diarrhea compared with 0% in the control arm.
Blurred vision and decreased visual acuity of any grade occurred in 12% of patients treated with IMBRUVICA (10% Grade 1, 2% Grade 2, no Grade 3 or higher) compared to 6% in the control arm (5% Grade 1 and <1% Grade 2 and 3). The median time to first onset was 96 days (range, 0 to 617) versus 109 days (range, 2 to 477) in IMBRUVICA-treated patients compared to the control arm, respectively. Of the patients who reported visual disturbances, 61% versus 71% had complete resolution and 39% versus 29% had not reported resolution at the time of analysis in IMBRUVICA-treated patients compared to the control arm, respectively. The median time from onset to resolution was 31 days (range, 1 to 457) versus 29 days (range, 1 to 253) in IMBRUVICA-treated subjects compared to the control arm, respectively.
The following adverse reactions have been identified during post-approval use of IMBRUVICA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
The coadministration of IMBRUVICA with a strong or moderate CYP3A inhibitor may increase ibrutinib plasma concentrations [see CLINICAL PHARMACOLOGY]. Increased ibrutinib concentrations may increase the risk of drug-related toxicity.
Dose modifications of IMBRUVICA are recommended when used concomitantly with posaconazole, voriconazole and moderate CYP3A inhibitors [see DOSAGE AND ADMINISTRATION].
Avoid concomitant use of other strong CYP3A inhibitors. Interrupt IMBRUVICA if these inhibitors will be used short-term (such as anti-infectives for seven days or less) [see DOSAGE AND ADMINISTRATION].
Avoid grapefruit and Seville oranges during IMBRUVICA treatment, as these contain strong or moderate inhibitors of CYP3A.
The coadministration of IMBRUVICA with strong CYP3A inducers may decrease ibrutinib concentrations. Avoid coadministration with strong CYP3A inducers [see CLINICAL PHARMACOLOGY].
Included as part of the PRECAUTIONS section.
Fatal bleeding events have occurred in patients treated with IMBRUVICA. Grade 3 or higher bleeding events (intracranial hemorrhage [including subdural hematoma], gastrointestinal bleeding, hematuria, and post procedural hemorrhage) have occurred in 3% of patients, with fatalities occurring in 0.3% of 1,011 patients exposed to IMBRUVICA in clinical trials. Bleeding events of any grade, including bruising and petechiae, occurred in 44% of patients treated with IMBRUVICA.
The mechanism for the bleeding events is not well understood.
IMBRUVICA may increase the risk of hemorrhage in patients receiving antiplatelet or anticoagulant therapies and patients should be monitored for signs of bleeding.
Consider the benefit-risk of withholding IMBRUVICA for at least 3 to 7 days pre and postsurgery depending upon the type of surgery and the risk of bleeding [see Clinical Studies].
Fatal and non-fatal infections (including bacterial, viral, or fungal) have occurred with IMBRUVICA therapy. Grade 3 or greater infections occurred in 24% of 1,011 patients exposed to IMBRUVICA in clinical trials. [see ADVERSE REACTIONS]. Cases of progressive multifocal leukoencephalopathy (PML) and Pneumocystis jirovecii pneumonia (PJP) have occurred in patients treated with IMBRUVICA. Consider prophylaxis according to standard of care in patients who are at increased risk for opportunistic infections. Monitor and evaluate patients for fever and infections and treat appropriately.
Treatment-emergent Grade 3 or 4 cytopenias including neutropenia (23%), thrombocytopenia (8%), and anemia (3%) based on laboratory measurements occurred in patients with B-cell malignancies treated with single agent IMBRUVICA.
Monitor complete blood counts monthly.
Fatal and serious cardiac arrhythmias have occurred with IMBRUVICA therapy. Grade 3 or greater ventricular tachyarrhythmias occurred in 0.2% of patients, and Grade 3 or greater atrial fibrillation and atrial flutter occurred in 4% of 1,011 patients exposed to IMBRUVICA inclinical trials. These events have occurred particularly in patients with cardiac risk factors, hypertension, acute infections, and a previous history of cardiac arrhythmias. See Additional Important Adverse Reactions.
Periodically monitor patients clinically for cardiac arrhythmias. Obtain an ECG for patients who develop arrhythmic symptoms (e.g., palpitations, lightheadedness, syncope, chest pain) or new onset dyspnea. Manage cardiac arrhythmias appropriately, and if it persists, consider the risks and benefits of IMBRUVICA treatment and follow dose modification guidelines [see DOSAGE AND ADMINISTRATION].
Hypertension has occurred in 12% of 1,011 patients treated with IMBRUVICA in clinical trials with a median time to onset of 5 months (range, 0.03 to 22 months). Monitor patients for new onset hypertension or hypertension that is not adequately controlled after starting IMBRUVICA. Adjust existing anti-hypertensive medications and/or initiate anti-hypertensive treatment as appropriate.
Other malignancies (9%) including non-skin carcinomas (2%) have occurred in 1,011 patients treated with IMBRUVICA in clinical trials. The most frequent second primary malignancy was non-melanoma skin cancer (6%).
Tumor lysis syndrome has been infrequently reported with IMBRUVICA therapy. Assess the baseline risk (e.g., high tumor burden) and take appropriate precautions. Monitor patients closely and treat as appropriate.
Based on findings in animals, IMBRUVICA can cause fetal harm when administered to a pregnant woman. Administration of ibrutinib to pregnant rats and rabbits during the period of organogenesis caused embryo-fetal toxicity including malformations at exposures that were 2-20 times higher than those reported in patients with hematologic malignancies. Advise women to avoid becoming pregnant while taking IMBRUVICA and for 1 month after cessation of therapy. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use In Specific Populations].
Advise the patient to read the FDA-approved patient labeling (PATIENT INFORMATION).
Ibrutinib was not carcinogenic in a 6-month rasH2 mouse study at oral doses up to 2000 mg/kg/day resulting in exposures approximately 23 (males) to 37 (females) times higher than the exposure in humans at a dose of 560 mg daily [see WARNINGS AND PRECAUTIONS].
Ibrutinib was not mutagenic in a bacterial mutagenicity (Ames) assay, was not clastogenic in a chromosome aberration assay in mammalian (CHO) cells, nor was it clastogenic in an in vivo bone marrow micronucleus assay in mice at doses up to 2000 mg/kg.
Rats were administered oral daily doses of ibrutinib for 4 weeks prior to pairing and during pairing in males and 2 weeks prior to pairing and during pairing in females. Treatment of female rats continued following pregnancy up to gestation day (GD) 7, and treatment of male rats continued until end of study. No effects on fertility or reproductive capacities were observed in male or female rats up to the maximum dose tested, 100 mg/kg/day (Human Equivalent Dose [HED] 16 mg/kg).
IMBRUVICA, a kinase inhibitor, can cause fetal harm based on findings from animal studies. There are no available data on IMBRUVICA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. In animal reproduction studies, administration of ibrutinib to pregnant rats and rabbits during the period of organogenesis at exposures up to 2-20 times the clinical doses of 420-560 mg daily produced embryofetal toxicity including structural abnormalities (see Data). If IMBRUVICA is used during pregnancy or if the patient becomes pregnant while taking IMBRUVICA, the patient should be apprised of the potential hazard to the fetus.
All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Animal Data
Ibrutinib was administered orally to pregnant rats during the period of organogenesis at doses of 10, 40 and 80 mg/kg/day. Ibrutinib at a dose of 80 mg/kg/day was associated with visceral malformations (heart and major vessels) and increased resorptions and post-implantation loss. The dose of 80 mg/kg/day in rats is approximately 14 times the exposure (AUC) in patients with MCL or MZL and 20 times the exposure in patients with CLL/SLL or WM administered the dose of 560 mg daily and 420 mg daily, respectively. Ibrutinib at doses of 40 mg/kg/day or greater was associated with decreased fetal weights. The dose of 40 mg/kg/day in rats is approximately 6 times the exposure (AUC) in patients with MCL administered the dose of 560 mg daily.
Ibrutinib was also administered orally to pregnant rabbits during the period of organogenesis at doses of 5, 15, and 45 mg/kg/day. Ibrutinib at a dose of 15 mg/kg/day or greater was associated with skeletal variations (fused sternebrae) and ibrutinib at a dose of 45 mg/kg/day was associated with increased resorptions and post-implantation loss. The dose of 15 mg/kg/day in rabbits is approximately 2.0 times the exposure (AUC) in patients with MCL and 2.8 times the exposure in patients with CLL/SLL or WM administered the dose of 560 and 420 mg daily, respectively.
There is no information regarding the presence of ibrutinib or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production.
The development and health benefits of breastfeeding should be considered along with the mother's clinical need for IMBRUVICA and any potential adverse effects on the breastfed child from IMBRUVICA or from the underlying maternal condition.
Verify the pregnancy status of females of reproductive potential prior to initiating IMBRUVICA therapy.
Females
Advise females of reproductive potential to avoid pregnancy while taking IMBRUVICA and for up to 1 month after ending treatment. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be informed of the potential hazard to a fetus.
Males
Advise men to avoid fathering a child while receiving IMBRUVICA, and for 1 month following the last dose of IMBRUVICA.
The safety and effectiveness of IMBRUVICA in pediatric patients has not been established. Pediatric studies have not been completed.
Of the 1011 patients in clinical studies of IMBRUVICA, 62% were ≥ 65 years of age, while 22% were ≥75 years of age. No overall differences in effectiveness were observed between younger and older patients. Anemia (all grades) and Grade 3 or higher pneumonia occurred more frequently among older patients treated with IMBRUVICA.
Avoid use of IMBRUVICA in patients with severe hepatic impairment (Child-Pugh class C). The safety of IMBRUVICA has not been evaluated in patients with mild to severe hepatic impairment by Child-Pugh criteria.
Dose modifications of IMBRUVICA are recommended in patients with mild or moderate hepatic impairment (Child-Pugh class A and B). Monitor patients for adverse reactions of IMBRUVICA closely [see DOSAGE AND ADMINISTRATION and CLINICAL PHARMACOLOGY].
Management of hyperviscosity in WM patients may include plasmapheresis before and during treatment with IMBRUVICA. Modifications to IMBRUVICA dosing are not required.
There is no specific experience in the management of ibrutinib overdose in patients. One healthy subject experienced reversible Grade 4 hepatic enzyme increases (AST and ALT) after a dose of 1680 mg. Closely monitor patients who ingest more than the recommended dosage and provide appropriate supportive treatment.
None
Ibrutinib is a small-molecule inhibitor of BTK. Ibrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. BTK's role in signaling through the B-cell surface receptors results in activation of pathways necessary for B-cell trafficking, chemotaxis, and adhesion. Nonclinical studies show that ibrutinib inhibits malignant B-cell proliferation and survival in vivo as well as cell migration and substrate adhesion in vitro.
In patients with recurrent B-cell lymphoma > 90% occupancy of the BTK active site in peripheral blood mononuclear cells was observed up to 24 hours after ibrutinib doses of ≥ 2.5 mg/kg/day (≥ 175 mg/day for average weight of 70 kg).
Ibrutinib demonstrated inhibition of collagen-induced platelet aggregation, with IC50 values at 4.6 μM (2026 ng/mL), 0.8 μM (352 ng/mL), and 3 μM (1321 ng/mL) in blood samples from healthy donors, donors taking warfarin, and donors with severe renal dysfunction, respectively. Ibrutinib did not show meaningful inhibition of platelet aggregation for ADP, arachidonic acid, ristocetin, and TRAP-6.
At a single dose 3 times the maximum recommended dose (1680 mg), IMBRUVICA did not prolong the QT interval to any clinically relevant extent.
Ibrutinib exposure increases with doses up to 840 mg (1.5 times the maximum approved recommended dosage) in patients with B-cell malignancies. The mean steady-state AUC (% coefficient of variation) observed in patients at 560 mg with MCL is 865 (69%) ng•h/mL and with MZL is 978 (82%) ng•h/mL, and in patients at 420 mg with CLL/SLL is 708 (71%) ng•h/mL, with WM is 707 (72%) ng•h/mL, and with cGVHD is 1159 (50%) ng•h/mL. Steady-state concentrations of ibrutinib without CYP3A inhibitors were achieved with an accumulation ratio of 1 to 1.6 after 1 week of multiple daily doses of 420 mg or 560 mg.
Absolute bioavailability of ibrutinib in fasted condition was 2.9% (90% CI: 2.1, 3.9) in healthy subjects. Ibrutinib is absorbed after oral administration with a median Tmax of 1 hour to 2 hours.
Effect Of Food
The administration of IMBRUVICA with a high-fat and high-calorie meal (800 calories to 1,000 calories with approximately 50% of total caloric content of the meal from fat) increased ibrutinib Cmax by 2- to 4-fold and AUC by approximately 2-fold, compared with administration of ibrutinib after overnight fasting.
In vitro studies suggest that ibrutinib is not a substrate of p-glycoprotein (P-gp) or breast cancer resistance protein (BCRP).
Reversible binding of ibrutinib to human plasma protein in vitro was 97.3% with no concentration dependence in the range of 50 ng/mL to 1000 ng/mL. The volume of distribution (Vd) was 683 L, and the apparent volume of distribution at steady state (Vd,ss/F) was approximately 10,000 L.
Intravenous clearance was 62 L/h in fasted conditions and 76 L/h in fed conditions. In line with the high first-pass effect, the apparent oral clearance is 2000 L/h in fasted conditions and 1000 L/h in fed conditions. The half-life of ibrutinib is 4 hours to 6 hours.
Metabolism
Metabolism is the main route of elimination for ibrutinib. It is metabolized to several metabolites primarily by cytochrome P450 (CYP) 3A and to a minor extent by CYP2D6. The active metabolite, PCI-45227, is a dihydrodiol metabolite with inhibitory activity towards BTK approximately 15 times lower than that of ibrutinib. The range of the mean metabolite to parent ratio for PCI-45227 at steady-state is 1 to 2.8.
Excretion
Ibrutinib, mainly in the form of metabolites, is eliminated primarily via feces. After a single oral administration of radiolabeled ibrutinib, 90% of radioactivity was excreted within 168 hours, with 80% excreted in the feces and less than 10% eliminated in urine. Unchanged ibrutinib accounted for 1% of the radiolabeled excreted dose in feces and none in urine, with the remainder of the excreted dose being metabolites.
Age and sex have no clinically meaningful effect on ibrutinib pharmacokinetics.
Mild and moderate renal impairment (creatinine clearance [CLcr] > 25 mL/min as estimated by Cockcroft-Gault equation) had no influence on the exposure of ibrutinib. No data is available in patients with severe renal impairment (CLcr < 25 mL/min) or in patients on dialysis.
The AUC of ibrutinib increased 2.7-fold in subjects with mild hepatic impairment (Child-Pugh class A), 8.2-fold in subjects with moderate hepatic impairment (Child-Pugh class B) and 9.8-fold in subjects with severe hepatic impairment (Child-Pugh class C) relative to subjects with normal liver function. The Cmax of ibrutinib increased 5.2-fold in mild hepatic impairment, 8.8-fold in moderate hepatic impairment and 7-fold in severe hepatic impairment relative to subjects with normal liver function [see Use In Specific Populations].
The coadministration of multiple doses of ketoconazole (strong CYP3A inhibitor) increased the Cmax of ibrutinib by 29-fold and AUC by 24-fold. The coadministration of multiple doses of voriconazole (strong CYP3A inhibitor) increased steady state Cmax of ibrutinib by 6.7-fold and AUC by 5.7-fold. Simulations under fed conditions suggest that posaconazole (strong CYP3A inhibitor) may increase the AUC of ibrutinib 3-fold to 10-fold.
The coadministration of multiple doses of erythromycin (moderate CYP3A inhibitor) increased steady state Cmax of ibrutinib by 3.4-fold and AUC by 3-fold.
The coadministration of rifampin (strong CYP3A inducer) decreased the Cmax of ibrutinib by more than 13-fold and AUC by more than 10-fold. Simulations suggest that efavirenz (moderate CYP3A inducer) may decrease the AUC of ibrutinib by 3-fold.
In vitro studies suggest that ibrutinib and PCI-45227 are unlikely to inhibit CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 or 3A at clinical doses. Both ibrutinib and PCI-45227 are unlikely to induce CYP1A2, CYP2B6 or CYP3A at clinical doses.
In vitro studies suggest that ibrutinib may inhibit BCRP and P-gp transport at clinical doses. The coadministration of oral P-gp or BCRP substrates with a narrow therapeutic index (e.g., digoxin, methotrexate) with IMBRUVICA may increase their concentrations.
The safety and efficacy of IMBRUVICA in patients with MCL who have received at least one prior therapy were evaluated in Study PCYC-1104-CA (referred to as Study 1104) (NCT01236391), an open-label, multi-center, single-arm trial of 111 previously treated patients. The median age was 68 years (range, 40 to 84 years), 77% were male, and 92% were Caucasian.
At baseline, 89% of patients had a baseline ECOG performance status of 0 or 1. The median time since diagnosis was 42 months, and median number of prior treatments was 3 (range, 1 to 5 treatments), including 11% with prior stem cell transplantation. At baseline, 39% of subjects had at least one tumor ≥ 5 cm, 49% had bone marrow involvement, and 54% had extranodal involvement at screening.
IMBRUVICA was administered orally at 560 mg once daily until disease progression or unacceptable toxicity. Tumor response was assessed according to the revised International Working Group (IWG) for non-Hodgkin's lymphoma (NHL) criteria. The primary endpoint in this study was investigator-assessed overall response rate (ORR). Responses to IMBRUVICA are shown in Table 16.
Table 16: Overall Response Rate (ORR) and Duration of
Response (DOR) Based on Investigator Assessment in Patients with MCL in Study
1104
| Total (N=111) |
|
| ORR (%) | 65.8 |
| 95% CI (%) | (56.2, 74.5) |
| CR (%) | 17.1 |
| PR (%) | 48.6 |
| Median DOR months (95% CI) | 17.5 (15.8, NE) |
| CI = confidence interval; CR = complete response; PR = partial response; NE = not evaluable | |
An Independent Review Committee (IRC) performed independent reading and interpretation of imaging scans. The IRC review demonstrated an ORR of 69%.
The median time to response was 1.9 months.
Upon initiation of IMBRUVICA, a temporary increase in lymphocyte counts (i.e., ≥ 50% increase from baseline and above absolute lymphocyte count of 5,000/mcL) occurred in 33% of patients in the MCL study. The onset of isolated lymphocytosis occurs during the first few weeks of IMBRUVICA therapy and resolves by a median of 8 weeks.
The safety and efficacy of IMBRUVICA in patients with CLL/SLL were demonstrated in one uncontrolled trial and three randomized, controlled trials.
Study PCYC-1102-CA (referred to as Study 1102) (NCT01105247), an open-label, multi-center trial, was conducted in 48 previously treated CLL patients. The median age was 67 years (range, 37 to 82 years), 71% were male, and 94% were Caucasian. All patients had a baseline ECOG performance status of 0 or 1. The median time since diagnosis was 80 months and the median number of prior treatments was 4 (range, 1 to 12 treatments). At baseline, 46% of subjects had at least one tumor ≥ 5 cm.
IMBRUVICA was administered orally at 420 mg once daily until disease progression or unacceptable toxicity. The ORR and DOR were assessed using a modified version of the International Workshop on CLL Criteria by an Independent Review Committee. The ORR was 58.3% (95% CI: 43.2%, 72.4%), all partial responses. None of the patients achieved a complete response. The DOR ranged from 5.6 to 24.2+ months. The median DOR was not reached.
The RESONATE study (A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma) (NCT01578707) was conducted in patients with previously treated CLL or SLL. Patients (n=391) were randomized 1:1 to receive either IMBRUVICA 420 mg daily until disease progression, or unacceptable toxicity or ofatumumab at an initial dose of 300 mg, followed one week later by a dose of 2000 mg weekly for 7 doses and then every 4 weeks for 4 additional doses. Fifty seven patients randomized to ofatumumab crossed over following progression to receive IMBRUVICA. The median age was 67 years (range, 30 to 88 years), 68% were male, and 90% were Caucasian. All patients had a baseline ECOG performance status of 0 or 1. The trial enrolled 373 patients with CLL and 18 patients with SLL. The median time since diagnosis was 91 months and the median number of prior treatments was 2 (range, 1 to 13 treatments). At baseline, 58% of patients had at least one tumor ≥ 5 cm. Thirty-two percent of patients had 17p deletion.
Efficacy results for RESONATE are shown in Table 17 and the Kaplan-Meier curves for PFS, assessed by an IRC according to IWCLL criteria, and OS are shown in Figures 1 and 2, respectively.
Table 17: Efficacy Results in Patients with CLL/SLL in
RESONATE
| Endpoint | IMBRUVICA N=195 |
Ofatumumab N=196 |
| Progression Free Survivalb | ||
| Number of events (%) | 35 (17.9) | 111 (56.6) |
| Disease progression | 26 | 93 |
| Death events | 9 | 18 |
| Median (95% CI), months | NE | 8.1 (7.2, 8.3) |
| HR (95% CI) | 0.22 (0.15, 0.32) | |
| Overall Survivala | ||
| Number of deaths (%) | 16 (8.2) | 33 (16.8) |
| HR (95% CI) | 0.43 (0.24, 0.79) | |
| Overall Response Rateb | 42.6% | 4.1% |
| a Median OS not evaluable for either arm b IRC evaluated. All partial responses achieved; none of the patients achieved a complete response. CI = confidence interval; HR = hazard ratio; NE = not evaluable |
||
Figure 1: Kaplan-Meier Curve of Progression Free
Survival (ITT Population) in Patients with CLL/SLL in RESONATE
 |
Figure 2: Kaplan-Meier Curve of Overall Survival (ITT
Population) in Patients with CLL/SLL in RESONATE
 |
RESONATE included 127 patients with del 17p CLL/SLL. The median age was 67 years (range, 30 to 84 years), 62% were male, and 88% were Caucasian. All patients had a baseline ECOG performance status of 0 or 1. PFS and ORR were assessed by an IRC. Efficacy results for del 17p CLL/SLL are shown in Table 18.
Table 18: Efficacy Results in Patients with del 17p
CLL/SLL in RESONATE
| Endpoint | IMBRUVICA N=63 |
Ofatumumab N=64 |
| Progression Free Survivala | ||
| Number of events (%) | 16 (25.4) | 38 (59.4) |
| Disease progression | 12 | 31 |
| Death events | 4 | 7 |
| Median (95% CI), months | NE | 5.8 (5.3, 7.9) |
| HR (95% CI) | 0.25 (0.14, 0.45) | |
| Overall Response Ratea | 47.6% | 4.7% |
| a IRC evaluated. All partial responses
achieved; none of the patients achieved a complete response. CI = confidence interval; HR = hazard ratio; NE = not evaluable |
||
RESONATE-2
The RESONATE-2 study (A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Tyrosine Kinase Inhibitor PCI-32765 versus Chlorambucil in Patients 65 Years or Older with Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma) (NCT01722487) was conducted in patients with treatment naïve CLL or SLL who were 65 years of age or older. Patients (n = 269) were randomized 1:1 to receive either IMBRUVICA 420 mg daily until disease progression or unacceptable toxicity, or chlorambucil at a starting dose of 0.5 mg/kg on Days 1 and 15 of each 28-day cycle for a maximum of 12 cycles, with an allowance for intrapatient dose increases up to 0.8 mg/kg based on tolerability.
The median age was 73 years (range, 65 to 90 years), 63% were male, and 91% were Caucasian. Ninety one percent of patients had a baseline ECOG performance status of 0 or 1 and 9% had an ECOG performance status of 2. The trial enrolled 249 patients with CLL and 20 patients with SLL. At baseline, 20% of patients had 11q deletion. The most common reasons for initiating CLL therapy include: progressive marrow failure demonstrated by anemia and/or thrombocytopenia (38%), progressive or symptomatic lymphadenopathy (37%), progressive or symptomatic splenomegaly (30%), fatigue (27%) and night sweats (25%).
With a median follow-up of 28.1 months, there were 32 observed death events [11 (8.1%) and 21 (15.8%) in IMBRUVICA and chlorambucil treatment arms, respectively]. With 41% of patients switching from chlorambucil to IMBRUVICA, the overall survival analysis in the ITT patient population resulted in a statistically significant HR of 0.44 [95% CI (0.21, 0.92)] and 2-year survival rate estimates of 94.7% [95% CI (89.1, 97.4)] and 84.3% [95% CI (76.7, 89.6)] in the IMBRUVICA and chlorambucil arms, respectively.
Efficacy results for RESONATE-2 are shown in Table 19 and the Kaplan-Meier curve for PFS, assessed by an IRC according to IWCLL criteria is shown in Figure 3.
Table 19: Efficacy Results in Patients with CLL/SLL in
RESONATE-2
| Endpoint | IMBRUVICA N=136 |
Chlorambucil N=133 |
| Progression Free Survivala | ||
| Number of events (%) | 15 (11.0) | 64 (48.1) |
| Disease progression | 12 | 57 |
| Death events | 3 | 7 |
| Median (95% CI), months | NE | 18.9 (14.1, 22.0) |
| HRb (95% CI) | 0.16 (0.09, 0.28) | |
| Overall Response Ratea (CR + PR) | 82.4% | 35.3% |
| P-value | <0.0001 | |
| a IRC evaluated; Five subjects (3.7%) in the
IMBRUVICA arm and two subjects (1.5%) in the Chlorambucil arm achieved complete
response b HR = hazard ratio; NE = not evaluable |
||
Figure 3: Kaplan-Meier Curve of Progression-Free
Survival (ITT Population) in Patients with CLL/SLL in RESONATE 2
 |
HELIOS
The HELIOS study (Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma) (NCT01611090) was conducted in patients with previously treated CLL or SLL. Patients (n = 578) were randomized 1:1 to receive either IMBRUVICA 420 mg daily or placebo in combination with BR until disease progression, or unacceptable toxicity. All patients received BR for a maximum of six 28-day cycles. Bendamustine was dosed at 70 mg/m² infused IV over 30 minutes on Cycle 1, Days 2 and 3, and on Cycles 2-6, Days 1 and 2 for up to 6 cycles. Rituximab was administered at a dose of 375 mg/m² in the first cycle, Day 1, and 500 mg/m² Cycles 2 through 6, Day 1.
The median age was 64 years (range, 31 to 86 years), 66% were male, and 91% were Caucasian. All patients had a baseline ECOG performance status of 0 or 1. The median time since diagnosis was 5.9 years and the median number of prior treatments was 2 (range, 1 to 11 treatments). At baseline, 56% of patients had at least one tumor > 5 cm and 26% presented with del11q.
Efficacy results for HELIOS are shown in Table 20 and the Kaplan-Meier curves for PFS are shown in Figure 4.
Table 20: Efficacy Results in Patients with CLL/SLL in
HELIOS
| Endpoint | IMBRUVICA + BR N=289 |
Placebo + BR N=289 |
| Progression Free Survivala | ||
| Number of events (%) | 56 (19.4) | 183 (63.3) |
| Median (95% CI), months | NE | 13.3 (11.3, 13.9) |
| HR (95% CI) | 0.20 (0.15, 0.28) | |
| Overall Response Ratea | 82.7% | 67.8% |
| a IRC evaluated, twenty-four subjects (8.3%)
in the IMBRUVICA + BR arm and six subjects (2.1%) in the placebo + BR arm achieved
complete response BR = bendamustine and rituximab; CI = confidence interval; HR = hazard ratio; NE = not evaluable |
||
Figure 4: Kaplan-Meier Curve of Progression-Free Survival
(ITT Population) in Patients with CLL/SLL in HELIOS
 |
Upon initiation of IMBRUVICA, an increase in lymphocyte counts (i.e., ≥ 50% increase from baseline and above absolute lymphocyte count of 5,000/mcL) occurred in 66% of patients in the CLL studies. The onset of isolated lymphocytosis occurs during the first month of IMBRUVICA therapy and resolves by a median of 14 weeks (range, 0.1 to 104 weeks). When IMBRUVICA was administered with chemoimmunotherapy, lymphocytosis was 7% with IMBRUVICA + BR versus 6% with placebo + BR.
The safety and efficacy of IMBRUVICA in patients with WM were demonstrated in two singlearm trials and one randomized, controlled trial.
The safety and efficacy of IMBRUVICA in WM were evaluated in Study PCYC-1118E (referred to as Study 1118) (NCT01614821), an open-label, multi-center, single-arm trial of 63 previously treated patients. The median age was 63 years (range, 44 to 86 years), 76% were male, and 95% were Caucasian. All patients had a baseline ECOG performance status of 0 or 1. The median time since diagnosis was 74 months, and the median number of prior treatments was 2 (range, 1 to 11 treatments). At baseline, the median serum IgM value was 3.5 g/dL (range, 0.7 to 8.4 g/dL).
IMBRUVICA was administered orally at 420 mg once daily until disease progression or unacceptable toxicity. The responses were assessed by investigators and an IRC using criteria adopted from the International Workshop of Waldenström’s Macroglobulinemia. Responses, defined as partial response or better, per IRC are shown in Table 21.
Table 21: Response Rate and Duration of Response (DOR)
Based on IRC Assessment in Patients with WM in Study 1118
| Total (N=63) |
|
| Response rate (CR+VGPR+PR), (%) | 61.9 |
| 95% CI (%) | (48.8, 73.9) |
| Complete Response (CR) | 0 |
| Very Good Partial Response (VGPR), (%) | 11.1 |
| Partial Response (PR), (%) | 50.8 |
| Median duration of response, months (range) | NE (2.8+, 18.8+) |
| CI = confidence interval; NE = not evaluable | |
The median time to response was 1.2 months (range, 0.7-13.4 months).
The INNOVATE monotherapy arm included 31 patients with previously treated WM who failed prior rituximab-containing therapy and received single-agent IMBRUVICA. The median age was 67 years (range, 47 to 90 years). Eighty-one percent of patients had a baseline ECOG performance status of 0 or 1, and 19% had a baseline ECOG performance status of 2. The median number of prior treatments was 4 (range, 1 to 7 treatments). The response rate observed in the INNOVATE monotherapy arm was 71% (0% CR, 29% VGPR, 42% PR). With a median follow-up time on study of 34 months (range, 8.6+ to 37.7 months), the median duration of response has not been reached.
INNOVATE
The INNOVATE study (A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination with Rituximab in Subjects with Waldenström’s Macroglobulinemia) (NCT02165397) was conducted in treatment naïve or previously treated patients with WM. Patients (n = 150) were randomized 1:1 to receive either IMBRUVICA 420 mg daily or placebo in combination with rituximab until disease progression or unacceptable toxicity. Rituximab was administered weekly at a dose of 375 mg/m² for 4 consecutive weeks (weeks 1-4) followed by a second course of weekly rituximab for 4 consecutive weeks (weeks 17-20). The major efficacy outcome measure is progression-free survival (PFS) assessed by an IRC with additional efficacy measure of response rate.
The median age was 69 years (range, 36 to 89 years), 66% were male, and 79% were Caucasian. Ninety-three percent of patients had a baseline ECOG performance status of 0 or 1, and 7% of patients had a baseline ECOG performance status of 2. Forty-five percent of patients were treatment naïve, and 55% of patients were previously treated. Among previously treated patients, the median number of prior treatments was 2 (range, 1 to 6 treatments). At baseline, the median serum IgM value was 3.2 g/dL (range, 0.6 to 8.3 g/dL), and MYD88 L265P mutations were present in 77% of patients, absent in 13% of patients, and 9% of patients were not evaluable for mutation status.
Efficacy results for INNOVATE as assessed by an IRC are shown in Table 22, and the Kaplan- Meier curves for PFS are shown in Figure 5.
Table 22: Efficacy Results in Patients with WM in
INNOVATE
| Endpoint | IMBRUVICA + R N=75 |
Placebo + R N=75 |
| Progression Free Survival | ||
| Number of events (%) | 14 (19) | 42 (56) |
| Median (95% CI), months | NE | 20.3 (13.7, 27.6) |
| HR (95% CI) | 0.20 (0.11, 0.38) | |
| P-valuea | <0.0001 | |
| Response Rate (CR+VGPR+PR)b | 72% | 32% |
| 95% CI | (0.62, 0.82) | (0.21, 0.43) |
| Complete Response (CR) | 3% | 1% |
| Very Good Partial Response (VGPR) | 23% | 4% |
| Partial Response (PR) | 47% | 27% |
| Median duration of response, months (range) | NE (1.9+, 36.4+) | 21.2 (4.6, 25.8) |
| CI = confidence interval; HR = hazard ratio; NE = not
evaluable; R = rituximab a P-value is from log-rank test stratified by WM IPSS (low, med, high) and number of prior systemic treatment regimens (0, ≥1) b P-value associated with response rate was <0.0001. Median follow-up time on study = 26.5 months |
||
Figure 5: Kaplan-Meier Curve of Progression-Free
Survival (ITT Population) in Patients with WM in INNOVATE
 |
An exploratory analysis demonstrated a sustained hemoglobin improvement (defined as increase of ≥ 2 g/dL over baseline for at least 8 weeks without blood transfusions or growth factor support) in 65% of patients in the IMBRUVICA + R group and 39% of patients in the placebo + R group.
The safety and efficacy of IMBRUVICA in MZL were evaluated in Study PCYC-1121-CA (referred to as Study 1121) (NCT01980628), an open-label, multi-center, single-arm trial of patients who received at least one prior therapy. The efficacy analysis included 63 patients with 3 sub-types of MZL: mucosa-associated lymphoid tissue (MALT; N=32), nodal (N=17), and splenic (N=14). The median age was 66 years (range, 30 to 92 years), 59% were female, and 84% were Caucasian. Ninety two percent of patients had a baseline ECOG performance status of 0 or 1 and 8% had ECOG performance status 2. The median time since diagnosis was 3.8 years, and the median number of prior treatments was 2 (range, 1 to 9 treatments).
IMBRUVICA was administered orally at 560 mg once daily until disease progression or unacceptable toxicity. The responses were assessed by investigators and an IRC using criteria adopted from the International Working Group criteria for malignant lymphoma. Responses per IRC are shown in Table 23.
Table 23: Overall Response Rate (ORR) and Duration of
Response (DOR) Based on IRC Assessment in Patients with MZL in Study 1121
| Total (N=63) |
|
| Response rate (CR + PR), (%) | 46.0% |
| 95% CI (%) | (33.4, 59.1) |
| Complete Response (CR), (%) | 3.2 |
| Partial Response (PR), (%) | 42.9 |
| Median duration of response, months (range) | NE (16.7, NE) |
| CI = confidence interval; NE = not evaluable Median follow-up time on study = 19.4 months |
|
The median time to response was 4.5 months (range, 2.3 to 16.4 months). Overall response rates were 46.9%, 41.2%, and 50.0% for the 3 MZL sub-types (MALT, nodal, splenic), respectively.
The safety and efficacy of IMBRUVICA in cGVHD were evaluated in Study PCYC-1129-CA (referred to as Study 1129) (NCT02195869), an open-label, multi-center, single-arm trial of 42 patients with cGVHD after failure of first line corticosteroid therapy and requiring additional therapy. The median age was 56 years (range, 19 to 74 years), 52% were male, and 93% were Caucasian. The most common underlying malignancies leading to transplantation were acute lymphocytic leukemia, acute myeloid leukemia, and CLL. The median time since cGVHD diagnosis was 14 months, the median number of prior cGVHD treatments was 2 (range, 1 to 3 treatments), and 60% of patients had a Karnofsky performance score of ≤ 80. The majority of patients (88 %) had at least 2 organs involved at baseline, with the most commonly involved organs being mouth (86%), skin (81%), and gastrointestinal tract (33%). The median daily corticosteroid dose (prednisone or prednisone equivalent) at baseline was 0.3 mg/kg/day, and 52% of patients were receiving ongoing immunosuppressants in addition to systemic corticosteroids at baseline. Prophylaxis for infections were managed per institutional guidelines with 79% of patients receiving combinations of sulfonamides and trimethoprim and 64% receiving triazole derivatives.
IMBRUVICA was administered orally at 420 mg once daily. The responses were assessed by investigators using the 2005 National Institute of Health (NIH) Consensus Panel Response Criteria with two modifications to align with the updated 2014 NIH Consensus Panel Response Criteria. Efficacy results are shown in Table 24.
Table 24: Best Overall Response Rate (ORR) and
Sustained Response Rate Based on Investigator Assessmenta in Patients with
cGVHD in Study 1129
| Total (N=42) |
|
| ORR | 28 (67%) |
| 95% CI | (51%, 80%) |
| Complete Response (CR) | 9 (21%) |
| Partial Response (PR) | 19 (45%) |
| Sustained response rateb | 20 (48%) |
| CI = confidence interval a Investigator assessment based on the 2005 NIH Response Criteria with two modifications (added “not evaluable” for organs with non-cGVHD abnormalities, and organ score change from 0 to 1 was not considered disease progression) b Sustained response rate is defined as the proportion of patients who achieved a CR or PR that was sustained for at least 20 weeks. |
|
The median time to response coinciding with the first scheduled response assessment was 12.3 weeks (range, 4.1 to 42.1 weeks). Responses were seen across all organs involved for cGVHD (skin, mouth, gastrointestinal tract, and liver).
ORR results were supported by exploratory analyses of patient-reported symptom bother which showed at least a 7-point decrease in Lee Symptom Scale overall summary score in 24% (10/42) of patients on at least 2 consecutive visits.
IMBRUVICA
(im-BRU-vih-kuh) (ibrutinib) capsules
IMBRUVICA
(im-BRU-vih-kuh) (ibrutinib) tablets
What is IMBRUVICA?
IMBRUVICA is a prescription medicine used to treat adults with:
It is not known if IMBRUVICA is safe and effective in children.
Before taking IMBRUVICA, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking IMBRUVICA with certain other medicines may affect how IMBRUVICA works and can cause side effects.
How should I take IMBRUVICA?
What should I avoid while taking IMBRUVICA?
What are the possible side effects of IMBRUVICA?
IMBRUVICA may cause serious side effects, including:
The most common side effects of IMBRUVICA in adults with B-cell malignancies (MCL, CLL/SLL, WM and MZL) include:
The most common side effects of IMBRUVICA in adults with cGVHD include:
Diarrhea is a common side effect in people who take IMBRUVICA. Drink plenty of fluids during treatment with IMBRUVICA to help reduce your risk of losing too much fluid (dehydration) due to diarrhea. Tell your healthcare provider if you have diarrhea that does not go away.
These are not all the possible side effects of IMBRUVICA.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store IMBRUVICA?
Keep IMBRUVICA and all medicines out of the reach of children.
General information about the safe and effective use of IMBRUVICA.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use IMBRUVICA for a condition for which it was not prescribed. Do not give IMBRUVICA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about IMBRUVICA that is written for health professionals.
What are the ingredients in IMBRUVICA?
Active ingredient: ibrutinib
Inactive ingredients:
IMBRUVICA capsules: croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. The 70 mg capsule shell contains gelatin, titanium dioxide, yellow iron oxide, and black ink. The 140 mg capsule shell contains gelatin, titanium dioxide, and black ink.
IMBRUVICA tablets: colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, and sodium lauryl sulfate. The film coating for each tablet contains ferrosoferric oxide (140 mg, 280 mg, and 420 mg tablets), polyvinyl alcohol, polyethylene glycol, red iron oxide (280 mg and 560 mg tablets), talc, titanium dioxide, and yellow iron oxide (140 mg, 420 mg, and 560 mg tablets).
This Patient Information has been approved by the U.S. Food and Drug Administration.
